Natera CFO Maps Multiple Paths to $6 Billion Revenue Target by 2029

Natera's CFO outlined plans to reach $6B revenue by 2029, citing growth in Signatera testing, Medicare coverage, and new patient acquisition. Signatera revenue is expected to exceed $1B this year, with a 2029 price target of $1,450. Natera is investing in R&D and clinical trials, with a potential U.S. launch of its colorectal cancer screening test in 2028-2029. The company is also targeting the Japanese market for Signatera.

Original reporting
Published Nov 15, 2026, 7:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 15, 2026, 7:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Natera CFO Maps Multiple Paths to $6 Billion Revenue Target by 2029 — source image
Decision brief

The 30-second read

$NTRABullishMed
01

Why it matters

The CFO's roadmap provides the first public multi‑year revenue target, setting a new valuation baseline for the stock.

02

Market read

New guidance could attract growth‑oriented investors and influence sector sentiment toward MRD testing companies.

03

What to watch

Potential delays in FDA approval and Medicare coverage could dampen revenue growth.

Relevance 6/10Novelty 6/10Timing: medium‑term outlook (2028‑2029)

Background

Natera is a diagnostics company focused on reproductive health, oncology and organ health, with its Signatera test central to its oncology portfolio.

Company-level read

Ticker impact

$NTRABullishHigh confidence
Context

CFO outlines a $6 billion revenue target by 2029 and projects >$1 billion in Signatera revenue this year, providing fresh guidance.

Expected impact

potential upward pressure as investors price in higher revenue expectations

Evidence & confidence

New multi‑year revenue target and near‑term $1 B forecast are primary disclosures not previously reported.

Market effects

Highlights growth potential in the MRD testing and early‑cancer detection sector.

U.S. diagnostics market may see increased investor interest.

Japan launch plans could add modest international exposure.

Counterpoint

Guidance may be overly optimistic; execution risk and reimbursement uncertainty could limit upside.

Key entities

  • Natera, Inc.

    Diagnostics firm providing genetic testing and molecular diagnostics.

  • Brodie Brophy

    Chief Financial Officer of Natera.

Related articles

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.

$NTRAMedAI 8/10

NTRA Q3 Loss Wider Than Expected, Revenues Beat, '26 Sales View Up

Natera reported a Q3 2026 adjusted loss of 39 cents per share, wider than expected, but revenues of $794M beat estimates. Oncology and women's health drove growth, with total tests up 34.1% YoY. The company raised 2026 revenue guidance to $3.005B-$3.035B. Gross margin improved, but operating loss narrowed. Cash flow remained positive.